Update on Glaucoma
UPDATE ON GLAUCOMA
January is National Glaucoma Awareness Month, but we evaluate and educate our patients every month of the year. Treatments for glaucoma in the U.S. are primarily eye drops, laser or occasional surgery. The CyPass Micro-Stent is a new surgical option that shows great promise and may make us reevaluate the order of our prescribed glaucoma therapies. Check out our blog below for more information. Enjoy!
Our surgeon, Dr. Aaron Porter, is now performing the CyPass Micro-Stent which is a new development in the treatment of glaucoma. This surgical procedure is performed during cataract surgery and is used for the treatment of Primary Open Angle Glaucoma. Patients with glaucoma may suffer from increased eye pressure which can cause vision loss.
The CyPass implant is placed between the sclera and ciliary body of the eye at the same time patients are undergoing cataract surgery. The stent is an extra step in maintaining a balanced eye pressure. When the stent is put in place, the device allows the liquid inside the eye to drain more freely and decrease the chance of an increase in eye pressure. One of the most important tasks in managing glaucoma is to monitor eye pressure to make sure that the patients’ levels are staying within a normal range.
One FDA study evaluated patients that were having cataract surgery along with the CyPass implant. Out of the 374 patients that received the implant, 73% of patients achieved lower eye pressures as opposed to the 58% that just had cataract surgery alone. Many patients are able to stop using their eye drops. The biggest advantage of the procedure is recovery time. Compared to the standard glaucoma procedure which has a recovery time of roughly three months, this surgery has a recovery time of just a few days. Click here to email our Glaucoma Clinical Health Coordinator, Katie, for any questions.
Posted on 01/26/2018 3:57 PM by Dr. Jeffrey Kegarise